Cargando…
Transglutaminase binding fusion protein linked to SLPI reduced corneal inflammation and neovascularization
BACKGROUND: To study the effect of topical administration of a fusion protein (PF-MC) made up of N-terminal portion of the protease inhibitor Trappin-2 (which is a substrate of transglutaminasa-2) and SLPI (protein with anti-inflammatory, anti-bacterial and anti-viral ability), in an animal model of...
Autores principales: | Salica, Juan P, Guerrieri, Diego, Maffia, Paulo, Croxatto, Juan O, Chuluyan, H Eduardo, Gallo, Juan E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603969/ https://www.ncbi.nlm.nih.gov/pubmed/25651862 http://dx.doi.org/10.1186/1471-2415-15-12 |
Ejemplares similares
-
Cementoin–SLPI fusion protein binds to human monocytes and epithelial cells and shows higher biological activity than SLPI
por: Maffía, Paulo C., et al.
Publicado: (2018) -
Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?
por: Ortiz, Gustavo, et al.
Publicado: (2014) -
Elucidating the mechanism of action of alpha-1-antitrypsin using retinal pigment epithelium cells exposed to high glucose. Potential use in diabetic retinopathy
por: Potilinski, María Constanza, et al.
Publicado: (2020) -
Proliferative retinopathy and neovascularization of the anterior segment in female type 2 diabetic rats
por: Mancini, Jorge E, et al.
Publicado: (2013) -
Secretory Leukocyte Protease Inhibitor (SLPI) Is, like Its Homologue Trappin-2 (Pre-Elafin), a Transglutaminase Substrate
por: Baranger, Kévin, et al.
Publicado: (2011)